Innate Pharma Analyst Ratings
Innate Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | 358.17% | HC Wainwright & Co. | → $11.5 | Reiterates | Buy → Buy |
| 09/18/2023 | 358.17% | HC Wainwright & Co. | → $11.5 | Reiterates | Buy → Buy |
| 06/16/2023 | 358.17% | HC Wainwright & Co. | → $11.5 | Reiterates | Buy → Buy |
| 03/24/2023 | 358.17% | HC Wainwright & Co. | → $11.5 | Reiterates | → Buy |
| 11/15/2022 | 258.57% | SVB Leerink | $10 → $9 | Maintains | Outperform |
| 09/16/2022 | 378.09% | Citigroup | $16 → $12 | Maintains | Buy |
| 08/02/2022 | 298.41% | SVB Leerink | $11 → $10 | Maintains | Outperform |
| 05/11/2022 | 338.25% | SVB Leerink | $10 → $11 | Maintains | Outperform |
| 09/17/2021 | 258.57% | SVB Leerink | $7 → $9 | Maintains | Outperform |
| 09/03/2021 | — | SVB Leerink | Upgrades | Market Perform → Outperform | |
| 09/02/2021 | — | SVB Leerink | Upgrades | Market Perform → Outperform | |
| 03/19/2021 | 178.88% | SVB Leerink | $5 → $7 | Maintains | Market Perform |
| 12/15/2020 | 99.2% | SVB Leerink | $7 → $5 | Downgrades | Outperform → Market Perform |
| 12/14/2020 | 358.17% | HC Wainwright & Co. | $13 → $11.5 | Maintains | Buy |
| 11/24/2020 | 89.24% | Goldman Sachs | → $4.75 | Initiates Coverage On | → Neutral |
| 09/09/2020 | 178.88% | SVB Leerink | $9 → $7 | Maintains | Outperform |
| 05/14/2020 | 258.57% | SVB Leerink | $10 → $9 | Maintains | Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/15/2023 | 358.17% | HC Wainwright & Co. | → 11.5 美元 | 重申 | 购买 → 购买 |
| 09/18/2023 | 358.17% | HC Wainwright & Co. | → 11.5 美元 | 重申 | 购买 → 购买 |
| 06/16/2023 | 358.17% | HC Wainwright & Co. | → 11.5 美元 | 重申 | 购买 → 购买 |
| 2023 年 3 月 24 日 | 358.17% | HC Wainwright & Co. | → 11.5 美元 | 重申 | → 购买 |
| 11/15/2022 | 258.57% | SVB Leerink | 10 美元 → 9 美元 | 维护 | 跑赢大盘 |
| 2022 年 9 月 16 日 | 378.09% | 花旗集团 | 16 美元 → 12 美元 | 维护 | 买 |
| 08/02/2022 | 298.41% | SVB Leerink | 11 美元 → 10 美元 | 维护 | 跑赢大盘 |
| 05/11/2022 | 338.25% | SVB Leerink | 10 美元 → 11 美元 | 维护 | 跑赢大盘 |
| 09/17/2021 | 258.57% | SVB Leerink | 7 美元 → 9 美元 | 维护 | 跑赢大盘 |
| 2021 年 3 月 9 日 | — | SVB Leerink | 升级 | 市场表现 → 跑赢大盘 | |
| 2021 年 2 月 9 日 | — | SVB Leerink | 升级 | 市场表现 → 跑赢大盘 | |
| 03/19/2021 | 178.88% | SVB Leerink | 5 美元 → 7 美元 | 维护 | 市场表现 |
| 2020 年 12 月 15 日 | 99.2% | SVB Leerink | 7 美元 → 5 美元 | 降级 | 跑赢大盘 → 市场表现 |
| 2020 年 12 月 14 日 | 358.17% | HC Wainwright & Co. | 13 美元 → 11.5 美元 | 维护 | 买 |
| 11/24/2020 | 89.24% | 高盛 | → 4.75 美元 | 启动覆盖范围开启 | → 中立 |
| 2020 年 9 月 9 日 | 178.88% | SVB Leerink | 9 美元 → 7 美元 | 维护 | 跑赢大盘 |
| 05/14/2020 | 258.57% | SVB Leerink | 10 美元 → 9 美元 | 维护 | 跑赢大盘 |
What is the target price for Innate Pharma (IPHA)?
Innate Pharma（IPHA）的目标价格是多少？
The latest price target for Innate Pharma (NASDAQ: IPHA) was reported by HC Wainwright & Co. on November 15, 2023. The analyst firm set a price target for $11.50 expecting IPHA to rise to within 12 months (a possible 358.17% upside). 4 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月15日公布了Innate Pharma（纳斯达克股票代码：IPHA）的最新目标股价。该分析公司将目标股价定为11.50美元，预计IPHA将在12个月内升至12个月内（可能上涨358.17％）。去年有4家分析公司公布了评级。
What is the most recent analyst rating for Innate Pharma (IPHA)?
Innate Pharma（IPHA）的最新分析师评级是多少？
The latest analyst rating for Innate Pharma (NASDAQ: IPHA) was provided by HC Wainwright & Co., and Innate Pharma reiterated their buy rating.
Innate Pharma（纳斯达克股票代码：IPHA）的最新分析师评级由HC Wainwright & Co. 提供，Innate Pharma重申了买入评级。
When is the next analyst rating going to be posted or updated for Innate Pharma (IPHA)?
Innate Pharma（IPHA）的下一次分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Innate Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Innate Pharma was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Innate Pharma的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Innate Pharma的最新评级是在2023年11月15日公布的，因此您应该预计下一个评级将在2024年11月15日左右公布。
Is the Analyst Rating Innate Pharma (IPHA) correct?
分析师对Innate Pharma（IPHA）的评级是否正确？
While ratings are subjective and will change, the latest Innate Pharma (IPHA) rating was a reiterated with a price target of $0.00 to $11.50. The current price Innate Pharma (IPHA) is trading at is $2.51, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但Innate Pharma（IPHA）的最新评级得到了重申，目标股价为0.00美元至11.50美元。Innate Pharma（IPHA）目前的交易价格为2.51美元，在分析师的预测区间内。